On-demand
Self-paced
1 hour (online)
Free
This online, self-paced, text-based module educates healthcare professionals towards a better understanding of the benefits and limitations of direct-to-consumer pharmacogenomic testing, when to pursue confirmatory clinical testing, and how to interpret pharmacogenomic test results using evidence-based resources.
It was developed by the National Human Genome Research Institute (NHGRI) Inter-Society Coordinating Committee for Practitioner Education in Genomics (ISCC-PEG).
To access, log in to our site (to right of this page; free registration) and enroll using one of the following methods:
- Free for all learners (via self-enrollment below)
- For continuing education credit (requires small fee; click 'Pay Now' below)
Planning Committee for the ISCC-PEG Pharmacogenomics Learning Series:
- Philip Empey, PharmD, PhD, FCCP (University of Pittsburgh School of Pharmacy)
- Andrew Monte, MD, PhD (University of Colorado)
- Trina Walker, DNP, APRN, FNP-C (Creighton University)
- Nguyen Park, MS, PA-C (National Human Genome Research Institute)
- Jeneva Gularte-Rinaldo, PhD, RN (Samuel Merritt University)
Course Directors
![Gammal](https://programs.test2learn.org/pluginfile.php/3518/course/summary/gammal%20125.jpg)
|
Roseann S. Donnelly (Gammal), PharmD, BCPS Associate Professor Massachusetts College of Pharmacy and Health Sciences
|
Additional Content Reviewers
- Cyrine-Eliana Haidar, PharmD, BCPS, BCOP, FASHP, Clinical Pharmacogenetics Coordinator, St. Jude Children’s Research Hospital
- David Kisor, PharmD, FCP, Professor of Pharmaceutical Sciences and Pharmacogenomics, Manchester University
TARGET AUDIENCE
All healthcare professionals
LEARNING OBJECTIVES
Upon completion of this activity, participants should be able to:
- Differentiate between the delivery models for pharmacogenomic testing.
- Identify the benefits and limitations of direct-to-consumer (DTC) pharmacogenomic testing.
- Interpret DTC pharmacogenomic test results.
- Evaluate the clinical actionability of genetic variants detected by a DTC pharmacogenomic test using evidence-based resources.
- Determine when confirmatory clinical testing is needed when faced with DTC pharmacogenomic test results.
- Explain why confirmatory clinical pharmacogenomic test results may differ from direct-to-consumer pharmacogenomic test results for the same patient.
- Discuss issues related to documenting DTC pharmacogenomic test results in the electronic health record.